DENVER, April 26, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced today that it will report its financial results for the full year ended December 31, 2020…


Previous articleNuminus Announces Phase 1 Clinical Trial of Natural Psilocybin Mushroom Extraction Prepared at Company Lab
Next articleCybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003